Natus Medical | Evaluate

Despair engulfs smaller device companies

The nightmare on the public markets is not confined to the bigger groups.

Natus goes private for $1.2bn

January 08, 2021

A tale of two Covids for smaller device makers

The pandemic provided the best and worst of times for smid-cap medtechs.

May 16, 2018

Sivantos-Widex allows EQT to reset the clock

January 14, 2014

Smaller cap medtech firms thrive on takeovers but suffer in court